Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 10/20 | 0.47 |
| ▸ | FAAH | O00519 | 9/20 | 0.46 |
| ▸ | CES1 | P23141 | 6/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465216 | 0.84 | FAAH (0.39) | DAGLAFAAHCES1HDAC6CYP1A2 | |
| SCHEMBL6468442 | 0.82 | DAGLA (0.55) | DAGLAFAAHCES1 | |
| SCHEMBL7048391 | 0.80 | FAAH (0.40) | DAGLAFAAHCES1HDAC6 | |
| SCHEMBL6462869 | 0.79 | DAGLA (0.52) | DAGLAFAAHCES1HDAC6 | |
| SCHEMBL6463188 | 0.76 | DAGLA (0.48) | DAGLAFAAHCES1 | |
| SCHEMBL7045524 | 0.75 | DAGLA (0.48) | DAGLAFAAHCES1 | |
| SCHEMBL6467366 | 0.75 | DAGLA (0.47) | DAGLAFAAHCES1 | |
| SCHEMBL6062463 | 0.75 | DAGLA (0.42) | DAGLAFAAHCES1 | |
| SCHEMBL6062834 | 0.74 | DAGLA (0.56) | DAGLAFAAHCES1 | |
| SCHEMBL7044860 | 0.74 | LMNA (0.44) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | DAGLA 2304/4885FAAH 479/4885CES1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.